Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

MannKind Corporation has announced positive preliminary results from phase 3 clinical trials evaluating its insulin therapy, Afrezza, in patients with type 1 and 2 diabetes. Afrezza is a novel ...

An FDA committee has given an overwhelming recommendation to new inhaled insulin treatment Afrezza. MannKind Corporation has spent years and many millions of dollars in developing the novel ...

The CDSCO decision follows existing approvals in the United States and Brazil. “Achieving approval for Afrezza in India, a country with the second highest burden of diabetes worldwide ...

Drugmaker Cipla has got regulatory approval to market Afrezza, a rapid acting insulin delivered through an inhaler, as compared to other insulins given through injections. The Central Drugs ...

MannKind (MNKD) and Cipla announced that the Central Drugs Standard Control Organisation in India has approved Afrezza Inhalation Powder in adults. The CDSCO decision follows existing approvals in ...